Effect of dextran on factor VIII and thrombus stability in humans. Significance of varying infusion rates.
The in vivo effect of dextran 70 on Factor VIII (antihemophilic factor) and thrombus stability has been studied in human volunteers after infusion at various rates. Varying the infusion time of dextran from 15 minutes to 2 hours did not result in any differences in the concentrations of dextran, fibrinogen and hematocrit, thus indicating similar degrees of hemodilution. Nor were any differences found in the effect of dextran on Factor VIII and thrombus stability. With regard to the antithrombotic function of dextran by hemodilution and effect on Factor VIII, there does not seem to be any advantage in giving dextran rapidly. This information could be of value in the treatment of elderly patients, for whom thrombosis prophylaxis is especially indicated and whose tolerance for hypervolemia is limited.
D002986:Clinical Trials as Topic; D003911:Dextrans / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D004341:Drug Evaluation; D005169:Factor VIII / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents; D006400:Hematocrit; D006801:Humans; D007263:Infusions, Parenteral; D013927:Thrombosis; D013997:Time Factors
D003911:Dextrans; D005343:Fibrinolytic Agents; D005169:Factor VIII; D005340:Fibrinogen